secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2023-07-20T23:59:59+00:00
Accession:  0001628280-23-025156
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott Q2 2023: Sales $10B, adjusted EPS $1.08; underlying base organic growth 11.5%
--------------------------------------------------------------------------------

- Q2 GAAP diluted EPS $0.78; adjusted diluted EPS $1.08; revenue $9,978M, down 11.4% reported (COVID testing decline).
- Underlying base business organic sales growth 11.5% led by Medical Devices (+14.2% organic) and Nutrition (+9.9% organic).
- Full-year 2023 adjusted EPS guidance reaffirmed at $4.30-$4.50; COVID testing sales forecast $1.3B.
- FreeStyle Libre sales $1.3B, up 24.7% organic; new product approvals: TactiFlex, AVEIR dual-chamber pacemaker.
- Quarterly dividend $0.51/share declared, payable Aug 15, 2023; 51 consecutive years of increases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000162828023025156/0001628280-23-025156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000162828023025156/abt-20230720.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-025156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer